Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study.
Open accessAbstract
Background: Multiple causes of false-positive chromogranin A (CgA) measurement have been reported that may affect its impact as a surrogate marker of RECIST progression in well-differentiated gastroenteropancreatic neuroendocrine tumors (WDGEPNET). Aims: 1) To evaluate the frequency of false-positive CgA results. 2) To prospectively compare CgA variations with RECIST morphological changes in patients without known causes of false-positive CgA measurements. Methods: First, the conditions responsible for potentially false-positive CgA measurements were screened in 184 consecutive patients with metastatic WDGEPNET. Secondly, a variation in CgA at a 6-month interval was compared to RECIST results at 6 months in 46 patients. Results: Among 184 patients, elevated CgA was found in 130 cases (71%) including 99 patients with at least one cause of a false-positive result. Impaired kidney function as well as medication with proton pump inhibitors were found to be the 2 major causes of false-positive results. The sensitivity and specificity of CgA measurements compared with morphological tumor changes according to the RECIST criteria were 71% and 50%, respectively, at 6 months. Conclusion: Routine screening for the causes of false-positive CgA measurements is mandatory in WDGEPNET patients. Our study does not validate the use of CgA as a surrogate marker of tumor progression.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Chromogranin A levels may also be elevated in other disease processes, such as prostate cancer, liver failure, cardiovascular diseases and renal failure.
“Chromogranin A levels may also be elevated in other disease processes, such as prostate cancer, liver failure, cardiovascular diseases and renal failure (Tramonti et al, 2001; Modlin et al, 2010; Vezzosi et al, 2011).”
From Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours (2011) · cites this paper as Vezzosi et al, 2011
The results (p. 96) identify renal failure and cardiac failure as conditions associated with elevated CgA. The paper does not establish the same point for liver failure or prostate cancer: it excludes severe hepatic dysfunction, and prostate carcinoma appears only in a reference title. (LLM, conf=0.87)
Experimental — accuracy not yet measuredVezzosi et al. studied 184 NET patients and found 130 elevated CgA results; at least one false-positive CgA result was found in 99 patients, mostly caused by PPI therapy and impaired kidney function.
“Vezzosi et al. (12) studied 184 NET patients and found 130 elevated CgA results.At least one false-positive CgA result was found in 99 patients, mostly caused by PPI therapy and impaired kidney function.”
From Effect of Short-Term Proton Pump Inhibitor Treatment and Its Discontinuation on Chromogranin A in Healthy Subjects (2012) · cites this paper as [12]
The results (p. 96) report elevated CgA in 130 of 184 patients; 99 of those 130 had a condition that could raise CgA, chiefly renal failure or proton-pump inhibitor treatment. The paper does not establish that all 99 had a false-positive result: it says the contribution of those conditions relative to tumor secretion remains uncertain. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works
Rindi, G., Klöppel, G., Couvelard, A., et al. (2007) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-007-0452-1 · Cited by 956 · see citing works
Histological Typing of Endocrine Tumours
Solcia, E., Klöppel, G., & Sobin, L. H. (2000) · Springer eBooks · doi:10.1007/978-3-642-59655-1 · Cited by 747 · see citing works
Yao, J. C., Lombard‐Bohas, C., Baudin, É., Kvols, L. K., Rougier, P. R., Ruszniewski, P. B., Hoosen, S., Peter, J. S., Haas, T., Lebwohl, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2669 · Cited by 648 · see citing works
Self-citationEkeblad, S., Skogseid, B. M., Dunder, K., Öberg, K., & Eriksson, B. K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0734 · Cited by 359 · see citing works
Nobels, F. R. E., Kwekkeboom, D. J., Coopmans, W., Schoenmakers, C. H. H., Lindemans, J. W., de Herder, W. W., Krenning, E. P., Bouillon, R., & Lamberts, S. W. J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.8.4145 · Cited by 355 · see citing works
Sundin, A., Vullierme, M., Kaltsas, G., et al. (2008) · Neuroendocrinology · doi:10.1159/000184855 · Cited by 287 · see citing works
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers
O’Toole, D., Grossman, A., Gross, D., Delle Fave, G., Barkmanova, J., O’Connor, J., Pape, U.-F., & Plöckinger, U. (2009) · Neuroendocrinology · doi:10.1159/000225948 · Cited by 268 · see citing works
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours
Baudin, É., Gigliotti, A., Ducreux, M. P., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.635 · Cited by 253 · see citing works
Self-citationChromogranin A: is it a useful marker of neuroendocrine tumors?
Campana, D., Nori, F., Piscitelli, L., Morselli-Labate, A. M., Pezzilli, R., Corinaldesi, R., & Tomassetti, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1535 · Cited by 248 · see citing works
Dietary factors and the survival of women with breast carcinoma
Holmes, M. D., Stampfer, M. J., Colditz, G. A., ROSNER, B. A., Hunter, D. J., & Willett, W. C. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990901)86:5 · Cited by 218 · see citing works
A comparison between three commercial kits for chromogranin A measurements
Stridsberg, M., Eriksson, B. K., Öberg, K., & Janson, E. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1770337 · Cited by 200 · see citing works
Arnold, R., Wilke, A., Rinke, A., MAYER, C., Kann, P. H., Klose, K., Scherag, A., Hahmann, M., Müller, H., & Barth, P. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.02.052 · Cited by 191 · see citing works
Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours
Nehar, D., Lombard‐Bohas, C., Olivieri, S., Claustrat, B., Chayvialle, J., Penes, M., Sassolas, G., & Borson‐Chazot, F. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02030.x · Cited by 177 · see citing works
Self-citationMyocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function
Pieroni, M., Corti, A., Tota, B., Curnis, F., Angelone, T., Colombo, B., Cerra, M. C., Bellocci, F., Crea, F., & Maseri, A. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm022 · Cited by 164 · see citing works
Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study
Zatelli, M. C., TORTA, M., Leon, A. E., Ambrosio, M. R., Gion, M., Tomassetti, P., de Braud, F., Fave, G. D., Dogliotti, L., & Uberti, E. C. D. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0001 · Cited by 157 · see citing works
Chromogranin A in uremia: Progressive retention of immunoreactive fragments
Hsiao, R. J., Mezger, M., & O’Connor, D. T. (1990) · Kidney International · doi:10.1038/ki.1990.71 · Cited by 152 · see citing works
Clinical significance of blood chromogranin A measurement in neuroendocrine tumours
Seregni, E. C., Ferrari, L., Bajetta, E., et al. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_2.s69 · Cited by 150 · see citing works
Chromogranin A Storage and Secretion
Hsiao, R. J., Parmer, R. J., TAKIYYUDDIN, M. A., & O’Connor, D. T. (1991) · Medicine · doi:10.1097/00005792-199101000-00003 · Cited by 125 · see citing works
Plasma chromogranin a in patients with inflammatory bowel disease
Sciola, V., Massironi, S., Conte, D., Caprioli, F., Ferrero, S., Ciafardini, C., PERACCHI, M., Bardella, M. T., & Piodi, L. P. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20851 · Cited by 123 · see citing works
Diagnostic value of plasma chromogranin A in neuroendocrine tumours
Tomassetti, P., Migliori, M., Simoni, P., Casadei, R., Iasio, R. D., Corinaldesi, R., & Gullo, L. (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200101000-00010 · Cited by 118 · see citing works
Welin, S., Stridsberg, M., Cunningham, J. L., Granberg, D. O., Skogseid, B. M., Eriksson, B. K., & Janson, E. T. (2009) · Neuroendocrinology · doi:10.1159/000179900 · Cited by 114 · see citing works
Giusti, M., Sidoti, M., Augeri, C., Rabitti, C., & Minuto, F. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500299 · Cited by 111 · see citing works
Impact of chromogranin A measurement in the work-up of neuroendocrine tumors
Baudin, É., Bidart, J., Bachelot, A., Ducreux, M. P., Elias, D. M., Ruffiè, P., & Schlumberger, M. J. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_2.s79 · Cited by 95 · see citing works
Self-citationPlasma Chromogranin A in Patients with Multiple Endocrine Neoplasia Type 1
Granberg, D. O., Stridsberg, M., Seensalu, R., et al. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.8.5938 · Cited by 90 · see citing works
Nikou, G. C., Marinou, K., Thomakos, P., Papageorgiou, D., Sanzanidis, V., Nikolaou, P., Kosmidis, C., Moulakakis, A., & Mallas, E. (2008) · Pancreatology · doi:10.1159/000152000 · Cited by 84 · see citing works
Measurements of chromogranin B can serve as a complement to chromogranin A
Stridsberg, M., Eriksson, B. K., Fellström, B., Kristiansson, G., & Janson, E. T. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.10.008 · Cited by 68 · see citing works
Chromogranin a and Pancreastatin-Like Immunoreactivity in Serum of Gastrinoma Patients
Syversen, U., Mignon, M., Bonfils, S., Kristensen, A., & Waldum, H. L. (1993) · Acta Oncologica · doi:10.3109/02841869309083906 · Cited by 68 · see citing works
Stivanello, M., Berruti, A., TORTA, M., Termine, A., Tampellini, M., Gorzegno, G., Angeli, A., & Dogliotti, L. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_2.s73 · Cited by 66 · see citing works
Abou‐Saif, A., Gibril, F., Ojeaburu, J. V., et al. (2003) · Cancer · doi:10.1002/cncr.11473 · Cited by 46 · see citing works
Potential clinical value of circulating chromogranin A in patients with prostate carcinoma
Berruti, A., Dogliotti, L., Mosca, A., et al. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_2.s153 · Cited by 41 · see citing works
Leon, A. E., TORTA, M., Dittadi, R., Uberti, E. C. D., Ambrosio, M. R., Fave, G. D., de Braud, F., Tomassetti, P., Gion, M., & Dogliotti, L. (2005) · The International Journal of Biological Markers · doi:10.1177/172460080502000303 · Cited by 33 · see citing works
Serum chromogranin A in the differential diagnosis of Cushing's syndrome
Nobels, F. R. E., de Herder, W. W., Kwekkeboom, D. J., Coopmans, W., Mulder, A., Bouillon, R., & Lamberts, S. W. J. (1994) · European Journal of Endocrinology · doi:10.1530/eje.0.1310589 · Cited by 31 · see citing works
Verderio, P., Dittadi, R., Marubini, E., Pizzamiglio, S., Gion, M., Appollonia, L. D., & Paradiso, A. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2007.251 · Cited by 24 · see citing works
Marie, I., Moutot, A., Tharrasse, A., et al. (2006) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2006.09.030 · Cited by 19 · see citing works
Serum Chromogranin A Concentration in Hyperthyroidism before and after Medical Treatment
Al-Shoumer, K. A. S., & Vasanthy, B. A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2231 · Cited by 14 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [14]14. Marie I, Moutot A, Tharrasse A, et al. Validity of proton pump inhibitors' prescriptions in a department of internal medicine. Rev Med Interne 2007; 28: 86-93.
- [36]36. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999; 86: 858-65. IJBM_2_2011.indb 101 7-06-2011 14:26:49
Cited by
Sorted by citations
Marotta, V., Zatelli, M. C., Sciammarella, C., Ambrosio, M. R., Bondanelli, M., Colao, A., & Faggiano, A. (2018) · Endocrine-Related Cancer · doi:10.1530/erc-17-0269 · Cited by 161 · see citing works
Mosli, H. H., Dennis, A., Kocha, W., Asher, L. J., & Van Uum, S. H. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1548 · Cited by 59 · see citing works
Korse, C. M., Muller, M., & Taal, B. G. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.380 · Cited by 47 · see citing works
“Chromogranin A levels may also be elevated in other disease processes, such as prostate cancer, liver failure, cardiovascular diseases and renal failure (Tramonti et al, 2001; Modlin et al, 2010; Vezzosi et al, 2011).”
Background
- Authors
- Vezzosi, D., Walter, T., Laplanche, A., Raoul, J. L., Dromain, C., Ruszniewski, P., d'Herbomez, M., Guigay, J., Mitry, E., Cadiot, G., Leboulleux, S., Lombard-Bohas, C., Borson-Chazot, F., Ducreux, M., Baudin, E., & (GTE), F. T. G. D. D. T. E.
- Affiliations
- Institut Gustave Roussy (FR)
- Hospices Civils de Lyon (FR)
- Centre Eugène Marquis (FR)
- Hôpital Beaujon (FR)
- Laboratoire de Médecine Nucléaire, Centre de Biologie-Pathologie, CHRU, Lille - France
- Hôpital Ambroise-Paré (FR)
- Centre Hospitalier Universitaire de Reims (FR)
- Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Oncologie Médicale, Lyon - France
- Fédération d'Endocrinologie Groupement Hospitalier Est, Bron - France
- Institut Gustave Roussy, Villejuif - France
- ORCID
- Venue
- The International Journal of Biological Markers
- Publisher
- SAGE Publications
- Published
- 2011-04
- Volume
- 26
- Issue
- 2
- Pages
- 94-101
- ISSN
- 0393-6155 (ISSN-L)
- 1724-6008
- OpenAlex
- W2032237900
- Semantic Scholar
- 665b51f50913272ce6c0b292a091e4b2ef660df9
- Cited by
- 43
- References
- 36
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 6 · 2020: 4 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 2 · 2015: 3 · 2014: 2 · 2013: 4 · 2012: 6
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The International Journal of Biological Markers (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Institut Gustave-Roussy
- Topics
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Neurology › Neuroblastoma Research and Treatments
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Keywords
- chromogranin A, false positives, metastatic neuroendocrine tumors, tumor progression markers, impaired kidney function, proton pump inhibitors, sensitivity and specificity
- MeSH terms
- Adult, Aged, False Positive Reactions, Female, Follow-Up Studies, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Pancreatic Neoplasms, Biomarkers, Tumor, Carcinoma, Neuroendocrine, Chromogranin A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
